Literature DB >> 23352962

Expression, function and cooperating partners of protease-activated receptor type 3 in vascular endothelial cells and B lymphocytes studied with specific monoclonal antibody.

Olena Kalashnyk1, Yuliya Petrova, Olena Lykhmus, Lyubov Mikhalovska, Sergiy Mikhalovsky, Anastasiya Zhukova, Dmitri Gnatenko, Wadie Bahou, Sergiy Komisarenko, Maryna Skok.   

Abstract

Receptor-specific antibodies can both prevent ligand-receptor interaction and initiate receptor signaling. Previously we generated monoclonal antibody 8E8 (mAb 8E8) against protease-activated receptor type 3 (PAR3) which inhibited proliferation of B cell hybridoma. Here we used mAb 8E8 and PAR1-specific polyclonal antibody to reveal the functions and cooperating partners of PAR3 in endothelial cells and in B lymphocytes. MAb 8E8 or PAR1 agonist peptide stimulated IL-6 and IL-8 production and VCAM-1 expression in HPMEC-ST1.6R cells. PAR1 antibody stimulated only VCAM-1 expression, while ICAM-1 expression was stimulated with mAB 8E8 or PAR3 peptide. MAb 8E8 stimulated weak mitogenic response, while PAR1 antibody inhibited it in normal but not in malignant B lymphocytes. Sandwich ELISA assay demonstrated the interaction of PAR3 with PAR1 in malignant cell lines and with IgM in normal B lymphocytes. It is concluded that PAR3 cooperates with PAR1 to mediate the effect of thrombin on cytokine production and VCAM-1 expression in endothelial cells and on cell proliferation in malignant B cells. ICAM-1 expression in endothelial cells requires PAR3 without PAR1. The inhibitory effect of thrombin in normal B lymphocytes is mediated by PAR1 alone, while mitogenic and pro-survival signaling in B lymphocytes is provided through PAR3 in cooperation with BCR.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23352962     DOI: 10.1016/j.molimm.2012.12.021

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  5 in total

Review 1.  Thrombin generation and activity in multiple sclerosis.

Authors:  Kelley R Jordan; Ivan Parra-Izquierdo; András Gruber; Joseph J Shatzel; Peter Pham; Larry S Sherman; Owen J T McCarty; Norah G Verbout
Journal:  Metab Brain Dis       Date:  2021-01-07       Impact factor: 3.584

2.  A Role for Protease Activated Receptor Type 3 (PAR3) in Nociception Demonstrated Through Development of a Novel Peptide Agonist.

Authors:  Juliet Mwirigi; Moeno Kume; Shayne N Hassler; Ayesha Ahmad; Pradipta R Ray; Changyu Jiang; Alexander Chamessian; Nakleh Mseeh; Breya P Ludwig; Benjamin D Rivera; Marvin T Nieman; Thomas Van de Ven; Ru-Rong Ji; Gregory Dussor; Scott Boitano; Josef Vagner; Theodore J Price
Journal:  J Pain       Date:  2021-01-09       Impact factor: 5.383

Review 3.  An overview on in vitro and in vivo antiviral activity of lactoferrin: its efficacy against SARS-CoV-2 infection.

Authors:  Luigi Rosa; Antimo Cutone; Maria Pia Conte; Elena Campione; Luca Bianchi; Piera Valenti
Journal:  Biometals       Date:  2022-08-03       Impact factor: 3.378

Review 4.  Evaluation on potential contributions of protease activated receptors related mediators in allergic inflammation.

Authors:  Huiyun Zhang; Xiaoning Zeng; Shaoheng He
Journal:  Mediators Inflamm       Date:  2014-04-30       Impact factor: 4.711

Review 5.  Protease-Activated Receptors and other G-Protein-Coupled Receptors: the Melanoma Connection.

Authors:  Rebecca A Rosero; Gabriel J Villares; Menashe Bar-Eli
Journal:  Front Genet       Date:  2016-06-15       Impact factor: 4.599

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.